Allergan Targets Hi-Tech Over IP For Glaucoma Generic

Law360, San Diego (January 27, 2012, 7:53 PM EST) -- Allergan Inc. lodged a patent infringement suit in Texas federal court on Friday seeking to stop Hi-Tech Pharmacal Co. Inc. from launching a generic version of Allergan's glaucoma medication Lumigan.

The Irvine, Calif.-based drugmaker brought its complaint after Hi-Tech sought federal approval of an abbreviated new drug application to make and sell bimatoprost ophthalmic solution, a generic version of Allergan’s Lumigan 0.01 percent product, throughout the U.S. before the expiration of Allergan’s patent.

Allergan received a letter on Jan. 3 from Amityville, N.Y.-based Hi-Tech asserting that...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.